QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
NASDAQ:ALLO

Allogene Therapeutics - ALLO Stock Forecast, Price & News

$7.20
-0.52 (-6.74%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.19
$7.75
50-Day Range
$5.62
$9.46
52-Week Range
$5.41
$17.49
Volume
1.28 million shs
Average Volume
1.86 million shs
Market Capitalization
$1.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.27

Allogene Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
181.6% Upside
$20.27 Price Target
Short Interest
Bearish
42.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.13mentions of Allogene Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$63,303 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.38) to ($2.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

317th out of 1,026 stocks

Biological Products, Except Diagnostic Industry

56th out of 167 stocks

ALLO stock logo

About Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Stock News Headlines

4 Biotech Stocks Set to Outpace Q4 Earnings Estimates
Free Stock Analysis Report: See the Right Way to Analyze Stocks
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. pixel
5 Analysts Have This to Say About Allogene Therapeutics
Free Stock Analysis Report: See the Right Way to Analyze Stocks
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. pixel
JMP Securities Keeps Their Buy Rating on Sutro Biopharma (STRO)
JMP Securities Keeps Their Buy Rating on Bicycle Therapeutics (BCYC)
JMP Securities Reaffirms Their Buy Rating on BioAtla (BCAB)
See More Headlines
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Company Calendar

Last Earnings
11/04/2021
Today
2/08/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLO
Fax
N/A
Employees
308
Year Founded
2018

Price Target and Rating

Average Stock Price Forecast
$20.27
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+181.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-257,010,000.00
Net Margins
-126,580.16%
Pretax Margin
-126,580.18%

Debt

Sales & Book Value

Annual Sales
$38.49 million
Book Value
$6.43 per share

Miscellaneous

Free Float
101,235,000
Market Cap
$1.04 billion
Optionable
Not Optionable
Beta
0.77

Social Links


Key Executives

  • David D. Chang
    President, Chief Executive Officer & Director
  • Eric Schmidt
    Chief Financial Officer
  • Barbra Sasu
    Chief Scientific Officer
  • Alison Moore
    Chief Technical Officer
  • Arun Balakumaran
    Chief Medical Officer













ALLO Stock - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALLO shares.
View ALLO analyst ratings
or view top-rated stocks.

What is Allogene Therapeutics' stock price forecast for 2023?

11 Wall Street research analysts have issued 12-month target prices for Allogene Therapeutics' shares. Their ALLO share price forecasts range from $9.00 to $32.00. On average, they anticipate the company's stock price to reach $20.27 in the next twelve months. This suggests a possible upside of 181.6% from the stock's current price.
View analysts price targets for ALLO
or view top-rated stocks among Wall Street analysts.

How have ALLO shares performed in 2023?

Allogene Therapeutics' stock was trading at $6.29 at the beginning of 2023. Since then, ALLO shares have increased by 14.5% and is now trading at $7.20.
View the best growth stocks for 2023 here
.

When is Allogene Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our ALLO earnings forecast
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its earnings results on Thursday, November, 4th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.01. The business earned $0.05 million during the quarter. Allogene Therapeutics had a negative trailing twelve-month return on equity of 37.74% and a negative net margin of 126,580.16%. During the same period last year, the business earned ($0.52) earnings per share.

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Nordea Investment Management AB (0.45%), Thrivent Financial for Lutherans (0.32%), Coastal Bridge Advisors LLC (0.28%), Swiss National Bank (0.14%), TD Asset Management Inc (0.12%) and Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.11%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends
.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $7.20.

How much money does Allogene Therapeutics make?

Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $1.04 billion and generates $38.49 million in revenue each year. The company earns $-257,010,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

The company employs 308 workers across the globe.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com.

This page (NASDAQ:ALLO) was last updated on 2/8/2023 by MarketBeat.com Staff